Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies

Background: Since the efficacy of ranibizumab (RBZ), bevacizumab (BVZ) and aflibercept (AFB) is comparable in neovascular age-related macular degeneration (AMD), we conducted a systematic review and meta-analysis to evaluate the long-term safety profiles of these agents, including ocular safety. Met...

Full description

Bibliographic Details
Main Authors: Anna A. Plyukhova, Maria V. Budzinskaya, Kirill M. Starostin, Robert Rejdak, Claudio Bucolo, Michele Reibaldi, Mario D. Toro
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Journal of Clinical Medicine
Subjects:
ranibizumab
bevacizumab
aflibercept
anti-vascular endothelial growth factor
neovascular age-related macular degeneration
meta-analysis
Online Access:https://www.mdpi.com/2077-0383/9/5/1522

Internet

https://www.mdpi.com/2077-0383/9/5/1522

Similar Items